Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease
Background The clinicopathological characteristics, treatment response and long-term outcome of immunoglobulin (Ig)A nephropathy with minimal change disease (MCD-IgAN) are not well defined. Methods Patients with biopsy-proven MCD-IgAN from the Jinling Hospital IgA nephropathy Registry were systemati...
Gespeichert in:
| Veröffentlicht in: | Journal of nephrology 2016-08, Vol.29 (4), p.567-573 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 573 |
|---|---|
| container_issue | 4 |
| container_start_page | 567 |
| container_title | Journal of nephrology |
| container_volume | 29 |
| creator | Li, Xiao-Wei Liang, Shao-Shan Le, Wei-Bo Cheng, Shui-Qin Zeng, Cai-Hong Wang, Jin-Quan Liu, Zhi-Hong |
| description | Background
The clinicopathological characteristics, treatment response and long-term outcome of immunoglobulin (Ig)A nephropathy with minimal change disease (MCD-IgAN) are not well defined.
Methods
Patients with biopsy-proven MCD-IgAN from the Jinling Hospital IgA nephropathy Registry were systematically reviewed and compared with those with IgA nephropathy without minimal change disease (Non-MCD-IgAN).
Results
We compared data of 247 MCD-IgAN patients and 1,121 Non-MCD-IgAN patients. Compared to Non-MCD-IgAN, MCD-IgAN patients were younger,with male predominance, had higher levels of proteinuria, total cholesterol and estimated glomerular filtration rate (eGFR), lower incidence of hypertension and microhematuria, lower level of serum creatinine, and had less severe glomerular, tubulointerstitial and vascular lesions in renal pathology. In the Non-MCD-IgAN group, 157 patients (14.0 %) reached the renal endpoint and 103 patients (9.2 %) entered end-stage renal disease (ESRD). The 5-,10-, 15- and 20-year cumulative renal survival rates from ESRD, calculated by Kaplan–Meier method, were 95.0, 83.0, 72.9 and 65.4 %, respectively. In the MCD-IgAN group, no patients entered ESRD and only 4 (1.6 %) reached the renal endpoint. Patients with MCD-IgAN had a significantly better renal outcome than Non-MCD-IgAN (
p
1.0 g/day, hypertension, eGFR |
| doi_str_mv | 10.1007/s40620-015-0242-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1804201740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1804201740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-147583091c4e6c68f1c5fb7e690be48007fb136c27f022eeec0a86d17d9ec14b3</originalsourceid><addsrcrecordid>eNp9kMtOxCAUhonRON4ewI1h6QY9UHpzNzHekknc6JpQejpTM4UKbSbzBL62jFV3uuIk_N8P5yPknMMVB8ivg4RMAAOeMhBSsHKPHPFcSJZBWu7HmQvOCimKGTkO4Q1ApKmQh2QmsjTJk7Q4Ih8LZ5dsQN9RNw7GdUhdQ5-Wc2qxX3nX62G1pZt2WNGutW2n19SstF0irduAOuAN1TRivfZtcJZWOGwQLY1ci3YIE6pt_TXEJ_6oOSUHjV4HPPs-T8jr_d3L7SNbPD883c4XzCRSDozLPC0SKLmRmJmsaLhJmyrHrIQKZRGlNBVPMiPyBoRARAO6yGqe1yUaLqvkhFxOvb137yOGQXVtMLhea4tuDIoXIAXwXEKM8ilqvAvBY6N6H3_ut4qD2vlXk38V_audf1VG5uK7fqw6rH-JH-ExIKZAiFdxf6_e3OhtXPmf1k8pWZJi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1804201740</pqid></control><display><type>article</type><title>Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Li, Xiao-Wei ; Liang, Shao-Shan ; Le, Wei-Bo ; Cheng, Shui-Qin ; Zeng, Cai-Hong ; Wang, Jin-Quan ; Liu, Zhi-Hong</creator><creatorcontrib>Li, Xiao-Wei ; Liang, Shao-Shan ; Le, Wei-Bo ; Cheng, Shui-Qin ; Zeng, Cai-Hong ; Wang, Jin-Quan ; Liu, Zhi-Hong</creatorcontrib><description><![CDATA[Background
The clinicopathological characteristics, treatment response and long-term outcome of immunoglobulin (Ig)A nephropathy with minimal change disease (MCD-IgAN) are not well defined.
Methods
Patients with biopsy-proven MCD-IgAN from the Jinling Hospital IgA nephropathy Registry were systematically reviewed and compared with those with IgA nephropathy without minimal change disease (Non-MCD-IgAN).
Results
We compared data of 247 MCD-IgAN patients and 1,121 Non-MCD-IgAN patients. Compared to Non-MCD-IgAN, MCD-IgAN patients were younger,with male predominance, had higher levels of proteinuria, total cholesterol and estimated glomerular filtration rate (eGFR), lower incidence of hypertension and microhematuria, lower level of serum creatinine, and had less severe glomerular, tubulointerstitial and vascular lesions in renal pathology. In the Non-MCD-IgAN group, 157 patients (14.0 %) reached the renal endpoint and 103 patients (9.2 %) entered end-stage renal disease (ESRD). The 5-,10-, 15- and 20-year cumulative renal survival rates from ESRD, calculated by Kaplan–Meier method, were 95.0, 83.0, 72.9 and 65.4 %, respectively. In the MCD-IgAN group, no patients entered ESRD and only 4 (1.6 %) reached the renal endpoint. Patients with MCD-IgAN had a significantly better renal outcome than Non-MCD-IgAN (
p
< 0.01). At multivariate Cox analysis, proteinuria >1.0 g/day, hypertension, eGFR <60 ml/min/1.73 m
2
, hypoproteinemia and hyperuricemia were independent risk factors of renal survival for Non-MCD-IgAN patients [hazard ratio (HR) 3.43,
p
< 0.001; HR 1.65,
p
< 0.05; HR 2.61,
p
< 0.001; HR 2.40,
p
< 0.001; HR 2.27,
p
< 0.001, respectively), but not for patients with MCD-IgAN.
Conclusions
The long-term outcome of patients with MCD-IgAN is significantly better than that of patients with Non-MCD-IgAN.]]></description><identifier>ISSN: 1121-8428</identifier><identifier>EISSN: 1724-6059</identifier><identifier>DOI: 10.1007/s40620-015-0242-9</identifier><identifier>PMID: 26537358</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Female ; Follow-Up Studies ; Glomerulonephritis, IGA - complications ; Glomerulonephritis, IGA - drug therapy ; Glomerulonephritis, IGA - pathology ; Glucocorticoids - therapeutic use ; Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrology ; Nephrosis, Lipoid - complications ; Original Article ; Prognosis ; Registries ; Risk Factors ; Survival Rate ; Urology</subject><ispartof>Journal of nephrology, 2016-08, Vol.29 (4), p.567-573</ispartof><rights>Italian Society of Nephrology 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-147583091c4e6c68f1c5fb7e690be48007fb136c27f022eeec0a86d17d9ec14b3</citedby><cites>FETCH-LOGICAL-c344t-147583091c4e6c68f1c5fb7e690be48007fb136c27f022eeec0a86d17d9ec14b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40620-015-0242-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40620-015-0242-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26537358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Xiao-Wei</creatorcontrib><creatorcontrib>Liang, Shao-Shan</creatorcontrib><creatorcontrib>Le, Wei-Bo</creatorcontrib><creatorcontrib>Cheng, Shui-Qin</creatorcontrib><creatorcontrib>Zeng, Cai-Hong</creatorcontrib><creatorcontrib>Wang, Jin-Quan</creatorcontrib><creatorcontrib>Liu, Zhi-Hong</creatorcontrib><title>Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease</title><title>Journal of nephrology</title><addtitle>J Nephrol</addtitle><addtitle>J Nephrol</addtitle><description><![CDATA[Background
The clinicopathological characteristics, treatment response and long-term outcome of immunoglobulin (Ig)A nephropathy with minimal change disease (MCD-IgAN) are not well defined.
Methods
Patients with biopsy-proven MCD-IgAN from the Jinling Hospital IgA nephropathy Registry were systematically reviewed and compared with those with IgA nephropathy without minimal change disease (Non-MCD-IgAN).
Results
We compared data of 247 MCD-IgAN patients and 1,121 Non-MCD-IgAN patients. Compared to Non-MCD-IgAN, MCD-IgAN patients were younger,with male predominance, had higher levels of proteinuria, total cholesterol and estimated glomerular filtration rate (eGFR), lower incidence of hypertension and microhematuria, lower level of serum creatinine, and had less severe glomerular, tubulointerstitial and vascular lesions in renal pathology. In the Non-MCD-IgAN group, 157 patients (14.0 %) reached the renal endpoint and 103 patients (9.2 %) entered end-stage renal disease (ESRD). The 5-,10-, 15- and 20-year cumulative renal survival rates from ESRD, calculated by Kaplan–Meier method, were 95.0, 83.0, 72.9 and 65.4 %, respectively. In the MCD-IgAN group, no patients entered ESRD and only 4 (1.6 %) reached the renal endpoint. Patients with MCD-IgAN had a significantly better renal outcome than Non-MCD-IgAN (
p
< 0.01). At multivariate Cox analysis, proteinuria >1.0 g/day, hypertension, eGFR <60 ml/min/1.73 m
2
, hypoproteinemia and hyperuricemia were independent risk factors of renal survival for Non-MCD-IgAN patients [hazard ratio (HR) 3.43,
p
< 0.001; HR 1.65,
p
< 0.05; HR 2.61,
p
< 0.001; HR 2.40,
p
< 0.001; HR 2.27,
p
< 0.001, respectively), but not for patients with MCD-IgAN.
Conclusions
The long-term outcome of patients with MCD-IgAN is significantly better than that of patients with Non-MCD-IgAN.]]></description><subject>Adult</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glomerulonephritis, IGA - complications</subject><subject>Glomerulonephritis, IGA - drug therapy</subject><subject>Glomerulonephritis, IGA - pathology</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Nephrosis, Lipoid - complications</subject><subject>Original Article</subject><subject>Prognosis</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Survival Rate</subject><subject>Urology</subject><issn>1121-8428</issn><issn>1724-6059</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOxCAUhonRON4ewI1h6QY9UHpzNzHekknc6JpQejpTM4UKbSbzBL62jFV3uuIk_N8P5yPknMMVB8ivg4RMAAOeMhBSsHKPHPFcSJZBWu7HmQvOCimKGTkO4Q1ApKmQh2QmsjTJk7Q4Ih8LZ5dsQN9RNw7GdUhdQ5-Wc2qxX3nX62G1pZt2WNGutW2n19SstF0irduAOuAN1TRivfZtcJZWOGwQLY1ci3YIE6pt_TXEJ_6oOSUHjV4HPPs-T8jr_d3L7SNbPD883c4XzCRSDozLPC0SKLmRmJmsaLhJmyrHrIQKZRGlNBVPMiPyBoRARAO6yGqe1yUaLqvkhFxOvb137yOGQXVtMLhea4tuDIoXIAXwXEKM8ilqvAvBY6N6H3_ut4qD2vlXk38V_audf1VG5uK7fqw6rH-JH-ExIKZAiFdxf6_e3OhtXPmf1k8pWZJi</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Li, Xiao-Wei</creator><creator>Liang, Shao-Shan</creator><creator>Le, Wei-Bo</creator><creator>Cheng, Shui-Qin</creator><creator>Zeng, Cai-Hong</creator><creator>Wang, Jin-Quan</creator><creator>Liu, Zhi-Hong</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160801</creationdate><title>Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease</title><author>Li, Xiao-Wei ; Liang, Shao-Shan ; Le, Wei-Bo ; Cheng, Shui-Qin ; Zeng, Cai-Hong ; Wang, Jin-Quan ; Liu, Zhi-Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-147583091c4e6c68f1c5fb7e690be48007fb136c27f022eeec0a86d17d9ec14b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glomerulonephritis, IGA - complications</topic><topic>Glomerulonephritis, IGA - drug therapy</topic><topic>Glomerulonephritis, IGA - pathology</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Nephrosis, Lipoid - complications</topic><topic>Original Article</topic><topic>Prognosis</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Survival Rate</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Xiao-Wei</creatorcontrib><creatorcontrib>Liang, Shao-Shan</creatorcontrib><creatorcontrib>Le, Wei-Bo</creatorcontrib><creatorcontrib>Cheng, Shui-Qin</creatorcontrib><creatorcontrib>Zeng, Cai-Hong</creatorcontrib><creatorcontrib>Wang, Jin-Quan</creatorcontrib><creatorcontrib>Liu, Zhi-Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Xiao-Wei</au><au>Liang, Shao-Shan</au><au>Le, Wei-Bo</au><au>Cheng, Shui-Qin</au><au>Zeng, Cai-Hong</au><au>Wang, Jin-Quan</au><au>Liu, Zhi-Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease</atitle><jtitle>Journal of nephrology</jtitle><stitle>J Nephrol</stitle><addtitle>J Nephrol</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>29</volume><issue>4</issue><spage>567</spage><epage>573</epage><pages>567-573</pages><issn>1121-8428</issn><eissn>1724-6059</eissn><abstract><![CDATA[Background
The clinicopathological characteristics, treatment response and long-term outcome of immunoglobulin (Ig)A nephropathy with minimal change disease (MCD-IgAN) are not well defined.
Methods
Patients with biopsy-proven MCD-IgAN from the Jinling Hospital IgA nephropathy Registry were systematically reviewed and compared with those with IgA nephropathy without minimal change disease (Non-MCD-IgAN).
Results
We compared data of 247 MCD-IgAN patients and 1,121 Non-MCD-IgAN patients. Compared to Non-MCD-IgAN, MCD-IgAN patients were younger,with male predominance, had higher levels of proteinuria, total cholesterol and estimated glomerular filtration rate (eGFR), lower incidence of hypertension and microhematuria, lower level of serum creatinine, and had less severe glomerular, tubulointerstitial and vascular lesions in renal pathology. In the Non-MCD-IgAN group, 157 patients (14.0 %) reached the renal endpoint and 103 patients (9.2 %) entered end-stage renal disease (ESRD). The 5-,10-, 15- and 20-year cumulative renal survival rates from ESRD, calculated by Kaplan–Meier method, were 95.0, 83.0, 72.9 and 65.4 %, respectively. In the MCD-IgAN group, no patients entered ESRD and only 4 (1.6 %) reached the renal endpoint. Patients with MCD-IgAN had a significantly better renal outcome than Non-MCD-IgAN (
p
< 0.01). At multivariate Cox analysis, proteinuria >1.0 g/day, hypertension, eGFR <60 ml/min/1.73 m
2
, hypoproteinemia and hyperuricemia were independent risk factors of renal survival for Non-MCD-IgAN patients [hazard ratio (HR) 3.43,
p
< 0.001; HR 1.65,
p
< 0.05; HR 2.61,
p
< 0.001; HR 2.40,
p
< 0.001; HR 2.27,
p
< 0.001, respectively), but not for patients with MCD-IgAN.
Conclusions
The long-term outcome of patients with MCD-IgAN is significantly better than that of patients with Non-MCD-IgAN.]]></abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>26537358</pmid><doi>10.1007/s40620-015-0242-9</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1121-8428 |
| ispartof | Journal of nephrology, 2016-08, Vol.29 (4), p.567-573 |
| issn | 1121-8428 1724-6059 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1804201740 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Female Follow-Up Studies Glomerulonephritis, IGA - complications Glomerulonephritis, IGA - drug therapy Glomerulonephritis, IGA - pathology Glucocorticoids - therapeutic use Humans Immunosuppressive Agents - therapeutic use Male Medicine Medicine & Public Health Middle Aged Nephrology Nephrosis, Lipoid - complications Original Article Prognosis Registries Risk Factors Survival Rate Urology |
| title | Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T10%3A23%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcome%20of%20IgA%20nephropathy%20with%20minimal%20change%20disease:%20a%20comparison%20between%20patients%20with%20and%20without%20minimal%20change%20disease&rft.jtitle=Journal%20of%20nephrology&rft.au=Li,%20Xiao-Wei&rft.date=2016-08-01&rft.volume=29&rft.issue=4&rft.spage=567&rft.epage=573&rft.pages=567-573&rft.issn=1121-8428&rft.eissn=1724-6059&rft_id=info:doi/10.1007/s40620-015-0242-9&rft_dat=%3Cproquest_cross%3E1804201740%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1804201740&rft_id=info:pmid/26537358&rfr_iscdi=true |